mercaptopurine has been researched along with Adenocarcinoma* in 49 studies
2 review(s) available for mercaptopurine and Adenocarcinoma
Article | Year |
---|---|
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
It has been proposed that effective disease control through abrogation of inflammation in IBD may also reduce CRC risk in these individual patients. This article summarizes the potential for medical therapy to reduce the risk of CRC via primary and secondary prevention, and offers practical ways in which a goal of mucosal improvement or healing may be incorporated into clinical practice. Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Intestinal Mucosa; Mercaptopurine; Mesalamine; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2014 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclophosphamide; Cytarabine; Female; Fluorouracil; Humans; Leukemia L1210; Leukemia, Lymphoid; Lymphoma; Melphalan; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Nitrogen Mustard Compounds; Prednisone; Pregnancy; Time Factors; Trophoblastic Neoplasms; Vinblastine | 1971 |
1 trial(s) available for mercaptopurine and Adenocarcinoma
Article | Year |
---|---|
6-Mercaptopurine (NSC-755) given intermittently in high doses: phase II study.
Topics: Adenocarcinoma; Anemia; Bone Marrow Diseases; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colonic Neoplasms; Humans; Leukopenia; Lung Neoplasms; Mercaptopurine; Nausea; Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thrombocytopenia; Vomiting | 1970 |
46 other study(ies) available for mercaptopurine and Adenocarcinoma
Article | Year |
---|---|
Inflammatory bowel disease treatment and non-melanoma skin cancer: a case report.
Immunosuppressant medications for Inflammatory Bowel Disease can help with both symptoms and disease progression. However, like immunosuppressants used in transplant patients, they are now suspect of contributing to nonmelenoma skin cancer (NMSC). Presented is a case of a 57-year-old Jewish man with Crohn's Disease who was diagnosed with a total of 84 NMSCs. We hope to elucidate the risk of immunosuppressants, particularly the thiopurines, on the development of NMSC. Topics: Adenocarcinoma; Crohn Disease; Fatal Outcome; Hawaii; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Male; Mercaptopurine; Middle Aged; Skin Neoplasms; Sunlight | 2012 |
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Pancreatic adenocarcinoma is one of the malignancies that is highly resistant to therapy and among the leading causes of cancer-related death. Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance. Members of this family's C-branch, also referred to as multidrug resistance-associated proteins (MRPs), might be of particular interest because they are able to efflux nucleoside analogs used in the treatment of pancreatic cancer. Expression of MRP1, MRP3, MRP4, and MRP5 in human pancreas and pancreatic carcinoma has been reported. However, contributions of MRPs to chemoresistance of pancreatic cancer are not fully understood. MRP5 mRNA expression in pancreatic adenocarcinoma cell lines correlated significantly with cellular sensitivity to 5-fluorouracil (5-FU) (r = 0.738, p < 0.05). Long-term treatment with 5-FU increased expression of MRP5 by 2.4-fold and was associated with significant drug resistance [IC(50) values for control and 5-fluorouracil (5-FU)-resistant Patu-T cell lines were 11.3 ± 5.3 and 33.2 ± 6.9 μM, respectively (p < 0.05)]. Consequently, overexpression of MRP5 in Colo-357 cells resulted in significantly reduced accumulation of 5-FU related radioactivity and 5-FU cytotoxicity. Knockdown of MRP5 significantly increased cellular cytotoxicity of 5-FU to Patu-02 cells and enhanced accumulation of radioactivity related to 5-FU and its metabolites. Our results suggest that MRP5 is expressed and functionally active and contributes to variable sensitivities of pancreatic adenocarcinoma cell lines to 5-FU. Further investigations using models that resemble human pancreas tumors are necessary to prove a causative relation between expression and activity of MRP5 and tumor resistance to 5-FU. Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Knockdown Techniques; Humans; Multidrug Resistance-Associated Proteins; Pancreas; Pancreatic Neoplasms; RNA; RNA Interference; Tumor Cells, Cultured | 2011 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.
Angiogenesis has been identified as an important target for antineoplastic therapy. The use of purine analogue antimetabolites in combination chemotherapy of solid tumors has been proposed. To assess the possibility that selected purine analogues may affect tumor neovascularization, 6-methylmercaptopurine riboside (6-MMPR), 6-methylmercaptopurine, 2-aminopurine, and adenosine were evaluated for the capacity to inhibit angiogenesis in vitro and in vivo. 6-MMPR inhibited fibroblast growth factor-2 (FGF2)-induced proliferation and delayed the repair of mechanically wounded monolayer in endothelial GM 7373 cell cultures. 6-MMPR also inhibited the formation of solid sprouts within fibrin gel by FGF2-treated murine brain microvascular endothelial cells and the formation of capillary-like structures on Matrigel by murine aortic endothelial cells transfected with FGF2 cDNA. 6-MMPR affected FGF2-induced intracellular signaling in murine aortic endothelial cells by inhibiting the phosphorylation of extracellular signal-regulated kinase-2. The other molecules were ineffective in all of the assays. In vivo, 6-MMPR inhibited vascularization in the chick embryo chorioallantoic membrane and prevented blood vessel formation induced by human endometrial adenocarcinoma specimens grafted onto the chorioallantoic membrane. Also, topical administration of 6-MMPR caused the regression of newly formed blood vessels in the rabbit cornea. Thus, 6-MMPR specifically inhibits both the early and the late phases of the angiogenesis process in vitro and exerts a potent anti-angiogenic activity in vivo. These results provide a new rationale for the use of selected purine analogues in combination therapy of solid cancer. Topics: 2-Aminopurine; Adenocarcinoma; Adenosine; Allantois; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aorta; Brain; Calcium-Calmodulin-Dependent Protein Kinases; Cattle; Cells, Cultured; Chick Embryo; Chorion; Cornea; Depression, Chemical; Endometrial Neoplasms; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Humans; Mercaptopurine; Methylthioinosine; Mice; Mitogen-Activated Protein Kinase 1; Neoplasm Transplantation; Neovascularization, Physiologic; Phosphorylation; Protein Processing, Post-Translational; Rabbits; Recombinant Fusion Proteins; Signal Transduction; Transfection | 1999 |
Study on the mechanism of immunopotentiating antitumor effect of 6-MPG, a water-soluble derivative of 6-mercaptopurine.
We investigated possible mechanisms of the antitumor action of gamma-(9H-purine-6-yl) thiomethyl L-glutamate (6-MPG), a water-soluble derivative of 6-MP. In the double grafted tumor system, BALB/c mice were inoculated intradermally with 10(6) cells of MethA fibrosarcoma at the right inguinal region on day 0 (the primary tumor) and later with 3 x 10(6) cells at the left on day 10 (the secondary tumor). Intraperitoneal administration of 6-MPG at a dose of 100 mg/kg/day from day 3 through 7 completely prevented growth of the secondary tumor. 6-MPG showed no effect on growth of colon 26 adenocarcinoma cells inoculated in place of the secondary MethA cells (antigen specificity). 6-MPG did not inhibit the secondary MethA growth in the BALB/c (nu/nu) mouse. The inhibitory effect of 6-MPG on the secondary tumor growth was diminished by prior treatment of the primed animals with cyclosporin A and anti-Thy antibody. Spleen cells from the tumor-bearing mice treated with 6-MPG showed a tumor-neutralizing activity (Winn assay). Treatment of the spleen cells with anti-CD8 antibody plus complement diminished the tumor-neutralizing effect but that with anti-CD4 antibody plus complement did not, indicating that CD8-positive cells are responsible for potentiation of the tumor immunity. These results suggest that the antitumor effect of 6-MPG against the secondary tumor is elicited by augmenting tumor specific T-cell production. Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Cyclosporine; Drug Interactions; Fibrosarcoma; Immunosuppressive Agents; Male; Mercaptopurine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phenotype; Solubility; Spleen; T-Lymphocytes; Water | 1997 |
[Nitroxyl radical Tempol as a modulator of toxic and antineoplastic effect of 6-mercaptopurine].
Both intact mice and those with transplantable adenocarcinoma 755 were used in the investigation. The nitroxyl radical Tempol was shown to cut down the toxicity of 6-mercaptopurine and potentiate its antitumor effect to a certain degree. The study results suggest on the basis of an investigation of cytochrome P450 and some other evidence that said effect of Tempol might be due, at least, in part to antioxidant activity. Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antioxidants; Cyclic N-Oxides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Male; Mercaptopurine; Mice; Mice, Inbred C57BL; Spin Labels; Survival Analysis | 1996 |
Carcinoma of the small intestine following treated acute myeloid leukaemia.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Daunorubicin; Humans; Ileal Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Thioguanine | 1990 |
[Growth characteristics of adenocarcinoma 755 recurrences in C57Bl/6 and (DBA/2 X C57Bl/6) F1 mouse strains].
Peculiarities of growth and recurrences of the adenocarcinoma 755 are studied in C57Bl/6 mice and hybrids (DBA/2 X +C57Bl/6)F1 after chemotherapy with cyclophosphamide and 6-mercaptopurine (6-MP). The growth rate of tumours was practically identical in the both mice strains. Growth rate of recurrences was slower in examined lines than in corresponding tumours. The obtained results showed that the antitumour effect of the drugs, in particularly of 6-MP, and the growth rate of the first and that of the second recurrences clearly depended on the tumour host strain. Topics: Adenocarcinoma; Animals; Cyclophosphamide; Drug Evaluation, Preclinical; Female; Mercaptopurine; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Recurrence, Local; Neoplasm Transplantation; Time Factors | 1988 |
[Kinetics of the cell population in adenocarcinoma 755 after cyclophosphane administration and rate of tumor growth after an additional course of therapy with cyclophosphane and 6-mercaptopurine].
The two injections of cyclophosphane (100 mg/kg) to mice with adenocarcinoma 755 on the 6th and 11th days after tumour transplantation had no influence on the cell cycle but induced a decrease of its growth rate due to an increase in the level of cell losses. The third cyclophosphane injection (the same dose) on the 17th day after the tumour transplantation or an additional course of five 6-mercaptopurine injections (50 mg/kg each dose) did not change essentially the growth rate of tumours. Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Mercaptopurine; Mice; Neoplasm Transplantation | 1985 |
Partial circumvention of resistance to 6-mercaptopurine by acylated P1,P2-bis(6-mercaptopurine-9-beta-D-ribofuranoside-5') pyrophosphate derivatives.
Topics: Adenocarcinoma; Animals; Bone Marrow; Cell Division; Cell Line; Dose-Response Relationship, Drug; Drug Resistance; Humans; Leukemia L1210; Mercaptopurine; Mice; Structure-Activity Relationship; Thioinosine; Thionucleotides | 1982 |
Occult adenocarcinoma of the pancreas in a 17-year-old patient with immunosuppressed leukemia.
Topics: Adenocarcinoma; Adolescent; Age Factors; Autopsy; Brain Neoplasms; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Mercaptopurine; Methotrexate; Neoplasms, Multiple Primary; Pancreas; Pancreatic Neoplasms; Prednisone; Vincristine | 1974 |
Studies with 8-azainosine, a cytotoxic nucleoside with antitumor activity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aza Compounds; Azaguanine; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Drug Resistance; Humans; Hypoxanthines; Imidazoles; Inosine; Leukemia L1210; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pentosyltransferases; Phosphotransferases; Purines | 1973 |
[Time factor in evaluating antineoplastic agents].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dactinomycin; Fluorouracil; Melphalan; Mercaptopurine; Methylthiouracil; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Nitrogen Mustard Compounds; Rats; Sarcoma, Experimental; Time Factors | 1972 |
[Antineoplastic and immunodepressive activity of purinylglutathionyl disulfide].
Topics: Adenocarcinoma; Animals; Antimetabolites; Glutathione; Immunosuppressive Agents; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Purines | 1972 |
Antitumor activity of cyclocytidine in a variety of tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line; Cyclization; Cyclophosphamide; Cytarabine; Cytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Leukemia L1210; Leukemia, Experimental; Male; Mercaptopurine; Methotrexate; Mice; Mitomycins; Neoplasms, Experimental; Sarcoma 180 | 1972 |
Antitumor activity of 5-formamido-1- D-ribofuranosylthioimidazole-4-carboxamide 2',3',5'-triformate in a variety of animal tumors.
Topics: Adenocarcinoma; Amides; Animals; Antineoplastic Agents; Ascites; Female; Formates; Guinea Pigs; Injections, Intraperitoneal; Leukemia L1210; Leukemia, Experimental; Male; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Nucleosides; Sarcoma, Experimental; Transplantation, Homologous | 1971 |
Formation and significance of 6-methylthiopurine ribonucleotide as a metabolite of 6-mercaptopurine.
Topics: Adenocarcinoma; Animals; Chromatography, Paper; Electrophoresis; Glucosyltransferases; L Cells; Leukemia L1210; Liver Neoplasms; Mercaptopurine; Methylation; Mice; Neoplasms, Experimental; Nucleosides; Nucleotides; Purines; Sulfur Isotopes | 1971 |
[A method of primary selection of antitumor agents].
Topics: Adenocarcinoma; Animals; Carcinoma 256, Walker; Chlorambucil; Cyclophosphamide; Melphalan; Mercaptopurine; Mice; Neoplasms, Experimental; Sarcoma, Experimental | 1971 |
[Changes in the ultrastructure of adenocarcinoma-755 under the influence of 6-mercaptopurine].
Topics: Adenocarcinoma; Animals; Cell Nucleolus; Cell Nucleus; Cytoplasmic Granules; Endoplasmic Reticulum; Mercaptopurine; Mice; Microscopy, Electron; Mitochondria; Neoplasms, Experimental | 1971 |
Acute erythromegakaryocytic leukaemia after treatment with cytostatic agents.
Topics: Adenocarcinoma; Aged; Bone Marrow Diseases; Erythrocytes; Humans; Leukemia; Lung Neoplasms; Male; Megakaryocytes; Mercaptopurine; Middle Aged; Thiotepa; Thrombocythemia, Essential | 1970 |
[Cytostatic therapy causing the loss of serological activity in thrombocytes].
Topics: ABO Blood-Group System; Absorption; Adenocarcinoma; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Dysgerminoma; Erythrocytes; Female; Hemagglutination Tests; Humans; Immune Sera; Isoantigens; Leukemia; Leukocytes; Male; Mercaptopurine; Methotrexate; Nitrogen Mustard Compounds; Pregnancy; Uracil Mustard | 1970 |
Hypoxanthine phosphoribosyltransferase and guanine metabolism of adenocarcinoma 755 cells.
Topics: Adenine; Adenocarcinoma; Buffers; Carbon Isotopes; Guanine; Hydrogen-Ion Concentration; Hypoxanthines; In Vitro Techniques; Kinetics; Mercaptopurine; Neoplasms, Experimental; Nucleotides; Purines; Thioguanine; Transferases | 1970 |
Feedback inhibition of purine biosynthesis in adenocarcinoma 755 and sarcoma 180 cells in culture.
Topics: Adenine; Adenocarcinoma; Animals; Azaserine; Carbon Isotopes; Cell Line; Feedback; Hypoxanthines; Mercaptopurine; Methotrexate; Neoplasms, Experimental; Nucleotides; Phosphotransferases; Purines; Sarcoma 180; Thioguanine | 1970 |
Purification and properties of 5-phosphoribosyl pyrophosphate amidotransferase from adenocarcinoma 755 cells.
Topics: Adenocarcinoma; Azoles; Binding Sites; Carbon Isotopes; Culture Techniques; Diphosphates; Female; Glutamine; Hot Temperature; Hydrogen-Ion Concentration; Kinetics; Magnesium; Mercaptopurine; Neoplasms, Experimental; Nucleotides; Quaternary Ammonium Compounds; Ribose; Sulfates; Transferases | 1969 |
The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antimetabolites; Cyclophosphamide; Mercaptopurine; Mice; Mitosis; Neoplasm Transplantation; Neoplasms, Experimental; Plasmacytoma; Sarcoma 180 | 1969 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamide; Dactinomycin; Female; Floxuridine; Fluorouracil; Hodgkin Disease; Humans; Melphalan; Mercaptopurine; Methotrexate; Nandrolone; Neoplasms; Nitrogen Mustard Compounds; Norethindrone; Prednisolone; Progesterone; Testosterone; Thiotepa; Uterine Neoplasms; Vinblastine | 1968 |
Lipid-soluble derivatives of 6-mercaptopurine.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chemical Phenomena; Chemistry; Leukemia L1210; Lipids; Mercaptopurine; Methods; Mice; Solubility | 1968 |
[Minimal useful dose of combined cytostatics in the treatment of inoperable pulmonary cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Drug Synergism; Humans; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitomycins; Neoplasm Metastasis; Radiotherapy Dosage; Triaziquone | 1968 |
[Modalities and results of anticancer polychemotherapy in 73 cases of advanced broncho-pleuro-pulmonary cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Vinblastine | 1968 |
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Mouth Neoplasms; Neoplasm Metastasis; Pharyngeal Neoplasms; Urogenital Neoplasms; Vinblastine | 1968 |
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betamethasone; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lectins; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Pleural Neoplasms; Sarcoma; Vinblastine | 1967 |
Effect of some synthetic alpha-N-alkyl glutamine derivatives on transplantable mouse tumours.
Topics: Adenocarcinoma; Alkylation; Animals; Antimetabolites; Carcinoma, Ehrlich Tumor; Glutamine; Leukemia, Experimental; Leukemia, Radiation-Induced; Mammary Neoplasms, Experimental; Mercaptopurine; Mice; Neoplasm Transplantation; Sarcoma 180 | 1967 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Culture Techniques; Flavonoids; Fluorouracil; HeLa Cells; Humans; Lung Neoplasms; Melphalan; Mercaptopurine; Methods; Mitomycins; Neoplasms; Rectal Neoplasms; Stomach Neoplasms | 1967 |
Association of cancer of the breast and acute myelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Leukemia, Myeloid; Lymphatic Metastasis; Mastectomy; Mercaptopurine; Methotrexate; Middle Aged | 1967 |
Thioguanine in deoxyribonucleic acid from tumors of 6-mercaptopurine-treated mice.
Topics: Adenocarcinoma; Animals; Chromatography, Paper; DNA, Neoplasm; Mercaptopurine; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Thioguanine | 1966 |
THE HUMAN TUMOR-EGG HOST SYSTEM. III. TUMOR-INHIBITORY PROPERTIES OF TENUAZONIE ACID.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo; Glycine; Mercaptopurine; Neoplasms; Neoplasms, Experimental; Puromycin; Pyrroles; Research; Saccharomyces; Tissue Culture Techniques; Triethylenemelamine | 1964 |
CHEMOTHERAPEUTIC CURE OF SPONTANEOUS MOUSE CANCER.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cortisone; Humans; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mercaptopurine; Mice; Neoplasms; Neoplasms, Experimental; Nitrogen Mustard Compounds; Pharmacology; Puromycin; Research; Sarcoma 180; Uracil Mustard; Zymosan | 1964 |
REMISSION OF METASTASES OF ERYTHROPOIETIN-SECRETING RENAL CELL ADENOCARCINOMA AFTER 6-MERCAPTOPURINE (NSC-755)-1 THERAPY.
Topics: Adenocarcinoma; Blood Cell Count; Carcinoma, Renal Cell; Epoetin Alfa; Erythropoietin; Geriatrics; Humans; Kidney Neoplasms; Lung Neoplasms; Mercaptopurine; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Nephrectomy | 1964 |
INHIBITION BY 6-MERCAPTOPURINE RIBONUCLEOTIDE OF THE CONVERSION OF INOSINIC ACID TO ADENYLIC ACID IN CELL-FREE SYSTEMS FROM MERCAPTOPURINESENSITIVE AND MERCAPTOPURINE-RESISTANT MAMMALIAN CELLS.
Topics: Adenine Nucleotides; Adenocarcinoma; Adenosine Monophosphate; Antimetabolites; Cell-Free System; Inosine Monophosphate; Mercaptopurine; Mice; Neoplasms, Experimental; Nucleotides; Pharmacology; Research; Ribonucleotides; Tissue Culture Techniques | 1964 |
DERIVATIVES OF PURINETHIOLS. PURINE THIOLCARBONATES AND RELATED COMPOUNDS.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbonates; Chemistry, Pharmaceutical; Leukemia L1210; Mercaptopurine; Mice; Purines; Research; Sarcoma 180; Tissue Culture Techniques | 1964 |
PLASMA CELL NEOPLASM ARISING IN A CAF MOUSE. CHARACTERISTICS AND RESPONSE TO CERTAIN CHEMOTHERAPEUTIC AGENTS.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Agents; Bence Jones Protein; Cecum; Cyclophosphamide; gamma-Globulins; Intestinal Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Neoplasms, Experimental; Neoplasms, Plasma Cell; Pathology; Pharmacology; Prednisolone; Radiation Effects; Research | 1964 |
Discovery of inhibitory activity of tenuazonic acid for growth of human adenocarcinoma-1.
Topics: Adenocarcinoma; Antineoplastic Agents; Azaserine; Humans; In Vitro Techniques; Infrared Rays; Magnetic Resonance Spectroscopy; Mercaptopurine; Mitosporic Fungi; Spectrum Analysis; Ultraviolet Rays | 1964 |
THE CHEMOTHERAPY OF ESTABLISHED SARCOMA 180 AND ADENOCARCINOMA 755 TUMORS WITH 6-THIOGUANINE.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Mercaptopurine; Mice; Neoplasms; Neoplasms, Experimental; Research; Sarcoma 180; Thioguanine; Toxicology | 1963 |
Evaluation of surgery and chemotherapy in the treatment of mouse mammary adenocarcinoma 755.
Topics: Adenocarcinoma; Animals; Breast; Intestinal Neoplasms; Mercaptopurine; Mice | 1962 |
THE PREPARATION AND ANTITUMOR ACTIVITY OF CERTAIN DERIVATIVES OF 6-MERCAPTOPURINE.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mercaptopurine; Mice; Pharmacology; Research | 1962 |
POTENTIAL PURINE ANTAGONISTS. XXXI. THE PREPARATION OF CERTAIN 9-ALKYL-2-AMINO-6-PURINETHIOLS AND RELATED DERIVATIVES AS ANTITUMOR AGENTS.
Topics: Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mercaptopurine; Pharmacology; Purines; Research; Sulfhydryl Compounds; Thioguanine | 1962 |